James N. Atkins, MD, Oncologist

James N. Atkins, MD

Dr. James N. Atkins has more than 20 years of medical oncology experience. In addition to being a clinical associate professor at Wake Forest University School of Medicine, he serves as director and co-principal investigator for one of the largest cancer-research organizations in the Southeast (Southeast Clinical Oncology Research Consortium). Dr. Atkins is board-certified in medical oncology and has been elected by his peers for inclusion in Best Doctors in America from 1996-2014. He has also authored a recent diet book.















BIBLIOGRAPHY

Articles:

Atkins  JN, Haponik EF.  Reye’s Syndrome in the Adult Patient.  Am J Med 1979; 67:672-678.

Atkins JN, Maternal Plasma Concentration of Pyridoxal Phosphate During Pregnancy: Adequacy of
Vitamin B-6 Supplementation While On Isoniazide Therapy.  Am Rev Respir Dis 1982;126:714-716.

Muss HB, Capizzi RL, Atkins JN, et al.  Phase I Trial of High-Dose Cytosine Arabinoside (HiDAC) and
HiDAC plus Cisplatin in Patients with Advanced Malignancies.  Semin Oncol 1985;289:110-113.

Atkins JN, Muss HB.  Microangiopathic Hemolytic Anemia in DiGuglielmo’s Syndrome.  Am J Med Science 1985;289:110-113.

Atkins JN, Muss HB, Capizzi RL, et al.  A Phase I Study of High-Dose Cytoarabine (Ara-C) and Cisplatin in Patients with Advanced Malignancy.  Cancer Treatment Reports 1985;69:897-899.

Jackson DV, Chauvenet AR, Callahan RD, Atkins JN, et al.  Phase II Trial of Vincristine Infusion in Acute Leukemia.  Cancer Chemother Pharmacol 1985;14:26-29.

Powell BL, Jackson DV, Scarantino CW, et al.  Sequential Hemibody and Local Irradiation with Combination Chemotherapy for Small Cell Lung Carcinoma:  A Preliminary Analysis.  Int J Radiation Oncology Biol Phys
1985;11:457-462.

Jackson DJ, Pope EK, McMahan RA, Cooper MR, Atkins JN, et al.  Clinical Trial of Pyridoxine to Reduce Vincristine Neurotoxocity.  Journal of Neuro-Oncology.  1986;4:37-41.

Powell BL, Muss HB, Capizzi RL, Caponera ME, White R, Zekan PJ, Atkins JN et al.  Phase I Study of High Dose Cytosine Arabinoside and Etoposide in Patients with Advanced Malignancies.  Cancer Chemotherapy and Pharmacology.  1987;19:250-252.

Craig JB, Powell BL, Jackson DV, Atkins JN, et al.  Phase II Trial of High-Dose Cytarabine and Cisplatin in Locoregional Previously Untreated Squamous Carcinoma of the Head and Neck: A Piedmont Oncology Association Study.  Cancer Treatment Reports.  1987; vol 71, no. 2:151-153.

Jackson DV, Wells HB, Atkins JN, et al.  Amelioration of Vincristine Neurotoxicity by Glutamic Acid.
Am J Med 1988; 84:1016-1022.

White DR, Powell BL, Craig JB, Stuart RG, Schnell FM, Goldklang GA, Atkins JN, et al.  Phase II Trial of High-Dose Cytarabine and Cisplatin in Previously Untreated Non-small Cell Carcinoma of the Lung:  A Piedmont Oncology Association Study.  Cancer 1990; vol 65, no 8:1700.

Atkins JN, Muss HB, Case LD, et al.  Leucovorin and High Dose Fluorouracil in Metastataic Prostate Cancer:  A Phase II Trial of the Piedmont Oncology Association.  Am J Clin Oncol 1996;19(1):23-25.

Muss HB, Case LD, Atkins JN, et al.  Tamoxifen versus High Dose Oral Medroxyprogesterone Acetate as Initial Endocrine Therapy for Patients with Metastatic Breast Cancer:  A Piedmont Oncology Associatiion (POA) Study.  J. Clin Oncol 1994 Aug;12(8):1630-8.

Fisher B, Digham J, Mamounas EP, Constantino JP, Wickerham DL, et al.  Sequential Methotrexate and Fluorouracil for the Treatment of Node-Negative Breast Cancer Patients with Estrogen Receptor-Negative Tumors:  Eight-Year Results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and First Report of Findings from NSABP B-19 Comparing Methotrexate and Fluorouracil.  J Clin Oncol 1996 Jul;14(7):1982-92.

Konsler G, Dalton JA, Carlson J, Atkins J.  Cancer Pain Management in North Carolina:  Physician Knowledge, Attitude, and Behavior.
NC Med J 1995 June;56(6):289-90.

Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham D, Bryant J, Dimitrove N, Abramson N,
Atkins J, et al.  Tamoxifen and Chemotherapy for Lymph Node Negative, Estrogen Receptor Positive Breast Cancer.  J NCI, vol. 89, No. 22, 1997 November 19: 1673-1682.

Schilling A, Conaway M, Wingate P, Atkins J, Berkowitz I, Clamon G, DiFino S, Vinciguerro V.  Recruiting Cancer Patients to Participate in Motivating Their Relatives to Quit Smoking:  A Cancer Control Study of the Cancer and Leukemia Group B (CALGB 9072).  Cancer Letter 1997.

Wolmark N, Bryant J, Smith R, Grem J, Allegra C, Hyams D, Atkins J, Dimitrov N, Oishi R, Prager D,
Fehrenbacker L, Romond E, Colangelo L, Fisher B.  Adjuvant 5-Fluorouracil and Leucovorin With or Without Interferon Alpha-2a in Colon Carcinoma:  National Surgical Adjuvant Breast and Bowel Project Protocol C-05.
J Natl Cancer Inst 1998;90:1810-6.

Fisher B, Costantino J, Wickerham D, Redmond C, Kavanah M, Cronin W, Vogel V, Robidoux A, Dimitrov N,
Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N, et al.  Tamoxifen for the Prevention of Breast Cancer:  Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.

Letters To The Editor:

Atkins JN.  Pregnancy and Hodgkin’s Disease.  Ann Intern Med 1982;96:531-532.

Atkins JN.  Granulocyte Transfusion.  Ann Intern Med 1983;98:114.

Atkins JN.  Flourouracil and the Palmar-Plantar Erythrodysesthesia Syndrome.  Ann Intern Med 1985;102:419.

Atkins JN.  Subcutaneous Morphine for Pain Control.  Palliative Medicine 1993;7(1):77.

Atkins JN.  Magic Lessons. . .  South Med J 1992;85:1153.

Atkins JN.  The Breast Cancer Prevention Trial:  A Correction.  JAMA 1994 November;272(17):1328.

Abstracts:

Atkins JN, Muss HB, Powell B, et al.  A Phase I Study of High-Dose Ara-C (HiDAC) and  Cisplatin.  Proc ACSO, p29,c-107, 1985.

Atkins J, Muss H, Capizzi R, et al.  A Phase I Study of High Dose Ara-C (HiDAC) in Patients with Solid Tumors.  Proc ASCO, p42,c-165, 1984.

Capizzi RL, Cooper MR, Pool M, et al.  Comparison of Total Dose (36g/m2 vs 24g/m2 and Dosing Interval (q6h vs q12h) of Ara-C with Sequential Asparaginase for Remission Induction in Previously Untreated Patients with ANLL.  Proc ASCO, p176,c-685,  1983.

Craig J, Jackson D, Moody D, et al.  Prospective Evaluation of changes in Computerized Cranial Tomography (CCT) in Patients with Small Cell Carcinoma (SCLC) Treated with Chemotherapy and Cranial Irradiation.
Proc ACSO, p224,c-875,  1984.

Muss HB, Capizzi RL, Atkins JN et al.  A Phase I  Dose-schedule Study of High-Dose Ara-C (HiDAC).
Proc ACSO, p29, c-108,  1985.

Muss H, Cooper R, Ferree C, et al.  Long-Term Follow-Up of L-Pam and CMF With and Without Radiation Therapy as Adjuvant Treatment for Stage II Breast Carcinoma.  Proc ASCO, p117,c-457,  1984.

Powell B, Jackson D, Scarantino C, et al.  Integration of Sequential Hemibody Radiation (SHB) into Conventional Chemotherapy-Local Radiation for Small Cell Lung Cancer.  Proc ASCO, p224,c-874,  1984.

Jackson DV, Case LD, White DR, et al.  Preliminary Trial of Pyridoxine to Reduce Vincristine Neurotoxicity.
Clinical Research, 32;5:854A,  1984.

Craig J, Jackson D, Case D, et al.  Timed Sequential Five Drug Combination Chemotherapy in the Treatment of Stage III-IV Squamous Cell Carcinoma of the Head and Neck.  Proceedings of the International Conference Head and Neck Cancer.  1:253,  1984.

Jackson DV, Sterchi JM, Morris DS, Long TR, Atkins JN, et al.  Continuous Intravenous Infusion of Vinca Alkaloids using a Subcutaneously Implanted Pump.  Clinical Research, 1984.

Craig J, Jackson D, Moody D, et al.  Prospective Evaluation of Changes in Computerized Cranial Tomography (CCT) in Patients with Small Cell Carcinoma (SCLC) Treated with Chemotherapy and Cranial Irradiation.
Proc ASCO 1984; 224:875.

Powell B, Capizzi R, Craig J, et al.  Therapeutic Index of High or Low Dose Ara-C (HgDAC or LoDAC) Induction Therapy for Acute Non-Lymphocytic Leukemia in Patients > Age 60.  Proc AACR, 4:177,  1985.

Beck J, Richards F, Rosenoff S, McCulloch J, Bradoff J, Atkins J, et al.  Cis Platinum and 5-Flourouracil as Combination Chemotherapy for Advanced Colorectal Cancer.  Proc ASCO 5:86,  1986.

Powell B, Capizzi R, Muss H, et al.  Low Dose Ara-C (LoDAC) Treatment of Acute Non-Lymphocytic Leukemia (ANLL) and Myelodysplastic Syndrome (MDS).  Proc ASCO, 5:166,  1986.

Jackson DV, Wells HB, Atkins JN et al.  Amelioration of Vincristine-Induced Neurotoxicity by Glutamic Acid:
Results of a Randomized Study of the Piedmont Oncology Association.  Proc AARC,  1987.

White DR, Powell BL, Muss HB, Spurr CL, et al.  High Dose Cytosine Arabinoside (HiDAC) and Cisplatin
(CDDP) as First-Line Chemotherapy in Non-Small Cell Lung Cancer:  A Phase II Trial of the Piedmont Oncology Association.  Proc ASCO, 6:668,  1987.

Jackson D, Cruz J, White D, Muss H, Atkins J, et al.  Cisplatinum in Extensive Cell Lung Cancer (SCLC):  A Randomized Trial by the Piedmont Oncology Association.  Proc ASCO,  1989.

Richards F, Muss H, Jackson D, Zekan P, Cooper R, Cruz J, Atkins J, et al.  Etoposide, Cisplatin and Vincristine in Recurrent Stage II or Stage III Non-Small Cell Lung Cancer:  A Phase II Trial of the Piedmont Oncology Association.  Proc AARC,  1989.

Richards F, Capizzi RL, Muss H, Cruz J, Powell B, White D, Jackson D, Atkins J, et al.  5-Flourouracil, High-Dose Folinic Acid, and Methotrexate for Advanced Colorectal Cancer:  A Phase II Trial of the Piedmont Oncology Association.  Proc ASCO, 1989.

Muss H, Case LD, Fussell R, Atkins J, et al.  Tamoxifen Versus High-Dose Oral Medroxyprogesterone Acetate
(MPA) as First Line Endocrine Therapy (RX) for Metastatic Breast Cancer (MBC):  A Randomized Trial of the Piedmont Oncology Association.  Proc ASCO,  1991.

White DR, Jackson DV, Russell GB, Muss HB, Loomer L, Atkins J, et al.  A Phase II Trial of Combination Vincristine (VCR) Infusion and High Dose Etoposide (VP-16) for Advanced Adenocarcinoma of the Lung.
Proc ASCO,  1991.

Richards F, Muss H, Jackson D, Atkins J, et al.  Combination of Vincristine (VCR) with High Dose Etoposide
(VP-16) in Untreated Extensive Small Cell Lung Cancer (SCLC).   A Phase II Dose Escalation Study of the Piedmont Oncology Association and the Southeast Cancer Control Consortium.  Proc ASCO,  1992.

Mamounas E, Brown A, Fisher B, Wickerham DL,  Sidhom M, Atkins J, et al.  3-Hour High-Dose Taxol Infusion in Advanced Breast Cancer:  An NSABP Phase II Study.  Proc ASCO,  1995.

Fisher B, Dignam J, DeCillis A, Wickerham D, Wolmark N, Emir B, Dimitrov N, Abramson N, Atkins J, et al.
The Worth of Chemotherapy and Tamoxifen (TAM) over TAM Alone in Node-Negative Patients with Estrogen-Receptor (ER) Positive Invasive Breast Cancer (BC):  First Results from NSABP B-20.  Proc ASCO,  1997.

Perry M, Ihde D, Herndon J, Atkins J, Pillemer E, Chahinian A, Green M.  Paclitaxel/Ifosfamide Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC).  Proc ASCO,  1997.

Ihde D, Perry M, Herndon J, Atkins J, Pillemer E, Chahinian A, Green M.  Vinorelbine/Ifosfamide Chemotherapy for Advanced Non-Small Cell Lung Cancer.  Proc ASCO, 1997.

Manmounas E, Brown A, Smith R, Lomborsky B, Fisher B, Wickerham DL, Wolmark N, Atkins J, Shibata H, Baez L, DeFusco P, Davila E, Thirlwell M, Bearden J, Tipping S, Scholnik A, NSABP Operations and Biostatistical Center, Pittsburgh, PA.  Effect of Taxol Duration of Infusion in Advanced Breast Cancer (ABC):  Results from NSABP B-26 Trial Comparing 3 to 24-hour Infusion of High-Dose Taxol.  Proc ASCO, Los Angeles, CA, May 1998.

Wolmark N, Bryant J, Hyams DM, Grem J, Atkins J, Dimitrov N, Fisher B, Oishi R, Prager D, Fehrenbacher L, Romond E, Colangelo L, NSABP Operations and Biostatistical Center, Pittsburg, PA.  The Relative Efficacy of

5-FU + Leucovorin (FU-LV) and 5-FU-LV + Interferon Alfa-2a (IFN) in Patients with Duke’s B and C Carcinoma of the Colon:  First Report of NSABP C-05.  Proc ASCO, Los Angeles, CA, May 1998.

To schedule an appointment with Dr. Atkins, call 844-316-7077. Or schedule an appointment using our easy online appointment request form.

To Request an Appointment

Call 919-580-0000

 

Or Use Our Easy Online Request Form!